Category: Licensing, IP, and Legal
Matters of legal in nature including licensing, intellectual property, and lawsuits.
Illumina Investigation Initiated by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Illumina, Inc. – ILMN
NEW ORLEANS, April 13, 2018 /PRNewswire/ — Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into Illumina, Inc. (Nasdaq: ILMN). During the first two quarters of 2016, the Company, which provides genetic sequencing products to customers in the... Read more
Rapid Mycoplasma Testing Method Now Accepted by Regulators for QA/QC and Lot Release
Rapid Mycoplasma Testing Method Now Accepted by Regulators for QA/QC and Lot Release MycoSEQ Mycoplasma Detection Method can accelerate production timelines for manufacturers of cell and gene therapies, biotherapeutics, vaccines and other cell-culture-based modalities BEDFORD, Mass., April 3, 2018 /PRNewswire/ — Manufacturers of cell-culture-based therapeutics can now rely on a faster method for detecting mycoplasma contamination.... Read more
Roche announces Japanese court ruled in favour of Chugai in Hemlibra patent litigation
Basel, 28 March 2018 Roche announces Japanese court ruled in favour of Chugai in Hemlibra patent litigation Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that a Japanese court (Tokyo District Court) ruled in favour of Chugai Pharmaceutical Co., Ltd, a member of the Roche Group, in the patent litigation case relating to Hemlibra® (emicizumab).... Read more
Roche announces Japanese court ruled in favour of Chugai in Hemlibra patent litigation
Basel, 28 March 2018 Roche announces Japanese court ruled in favour of Chugai in Hemlibra patent litigation Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that a Japanese court (Tokyo District Court) ruled in favour of Chugai Pharmaceutical Co., Ltd, a member of the Roche Group, in the patent litigation case relating to Hemlibra® (emicizumab).... Read more
New Salmonella Multiplex PCR Solution for Simultaneous Detection of Three Salmonella Targets in One Rapid Test is Now Certified by AFNOR
New Salmonella Multiplex PCR Solution for Simultaneous Detection of Three Salmonella Targets in One Rapid Test is Now Certified by AFNOR Real-Time PCR workflow gains NF VALIDATION by AFNOR Certification for rapid and simultaneous detection of Salmonella species, Salmonella Typhimurium and Salmonella Enteritidis BASINGSTOKE, England, March 27, 2018 /PRNewswire/ — Laboratories performing tests for poultry producers... Read more
Pacific Biosciences Prevails in Patent Eligibility Ruling Against Oxford Nanopore
MENLO PARK, Calif., March 22, 2018 (GLOBE NEWSWIRE) — Pacific Biosciences of California, Inc. (Nasdaq:PACB), the leader in long-read, high-resolution sequencing, today announced that Judge Leonard P. Stark of the U.S. District Court for the District of Delaware denied a motion to dismiss filed on December 14, 2017 by Oxford Nanopore Technologies, Inc., a wholly-owned... Read more
SIGNA Premier Licensed by Health Canada
Toronto, Canada – March 20, 2018 – GE Healthcare is proud to announce SIGNA™ Premier, a new wide bore 3.0T magnetic resonance imaging (MRI) system, is now available for sale in Canada. SIGNA Premier is the result of a four-year collaboration with the National Football League (NFL) and research institutions around the world working to design... Read more
New Agreements Underscore QIAGEN’s Leadership in Bioinformatics
HILDEN, Germany and AARHUS, Denmark, February 2, 2016 /PRNewswire/ — QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced new partnerships to enhance the profile and expand the use of its market leading bioinformatics solutions for microbiome, metagenomics and other applications. QIAGEN Bioinformatics signed an agreement with genomics big data company CosmosID, Inc. to... Read more